Many oncoproteins are considered undruggable because they lack enzymatic activities. In this study, we present a small molecule-based anticancer agent that acts by inhibiting dimerization of the oncoprotein survivin, thereby promoting its degradation along with spontaneous apoptosis in cancer cells. Through a combination of computational analysis of the dimerization interface and in-silico screening, we identified one compound that induced proteasome-dependent survivin degradation. Analysis of a set of structural analogues led us to identify a lead compound (LQZ-7F) which was effective in blocking the survival of multiple cancer cell lines in a low micromolar concentration range. LQZ-7F induced proteasome-dependent survivin degradation, mitotic arrest, apoptosis, and it blocked the growth of human tumors in mouse xenograft assays. In addition to providing preclinical proof of concept for a survivin-targeting anticancer agent, our work offers novel in silico screening strategies to therapeutically target homo-dimeric oncogenic proteins considered undruggable.
Introduction
Survivin is a member of the Inhibitor of apoptosis (IAP) gene family containing a single Baculovirus IAP Repeat (BIR) domain, a zinc-finger fold, and an extended C-terminal helical coiled coil (1) . It is a homo-dimer of a 16.5-kDa protein (2, 3) . Ectopic survivin over-expression causes inhibition of cell death induced by intrinsic and extrinsic stimuli in cell lines (4) (5) (6) (7) (8) (9) and in animals (10) . Survivin is over-expressed essentially in all cancers, but not expressed in most adult normal tissues (1, 11) . Survivin has also been shown to contribute to radiotherapy and chemotherapy resistance, and inhibition of survivin sensitizes cancer cells to these treatments (12) (13) (14) . Treatments with molecular probes such as antisense oligonucleotide, ribozyme, siRNA, and dominant negative mutant all resulted in caspase-dependent cell death and increased apoptosis induced by radiation and anticancer drugs (6, (14) (15) (16) (17) (18) (19) . These findings clearly established survivin as an ideal target for discovery of anticancer therapeutics.
Unfortunately, survivin belongs to a group of proteins that are considered undruggable due to lack of enzymatic activities. Although small molecule inhibitors have been identified that would interfere with the function of this type of proteins by blocking their interaction with other essential proteins, this approach has not led to drug candidates for clinical trials except in rare cases. In the case of survivin, targeting its expression has been attempted to avoid targeting survivin protein directly. For example, YM155, a small molecule compound, has been identified to inhibit survivin expression by targeting its transcription (20) and later was shown to inhibit transcription factors such as SP1 (21) . However, several phase II trials of YM155 showed only limited or modest at best efficacy on human cancers (21) . An antisense oligonucleotide, LY2181308, that inhibits survivin expression has also been tested as a single agent in phase I trial for solid tumors (22) and in combination with docetaxel in phase II trial for castration-resistant prostate cancers (23) . 4 Unfortunately, neither of these two trials showed any benefit of using LY2181308. Thus, new inhibitors of survivin are clearly needed perhaps by developing a strategy to target directly at the survivin protein itself.
It is known that exposure of the hydrophobic interface of a dimeric protein often leads to conformational change (24, 25) , which causes destabilization and degradation of the protein by proteasome or autophagy (26) . Because survivin exists as a homo-dimer, we hypothesized that a small molecule compound that inhibits survivin dimerization may promote survivin degradation via the proteasome and, thus, eliminates the protein and leads to spontaneous apoptosis. We recently developed a novel strategy to identify interfacial hydrophobic core units critical for homodimerization (27, 28) . Using this strategy, we tested the above hypothesis by first identifying the hydrophobic core residues critical for survivin dimerization followed by in-silico screening for inhibitors targeting the critical core residues as well as in-vitro and cell-based assays. We identified a hit compound, LQZ-7, which dissociated dimeric survivin and induced proteasome-dependent survivin degradation. Further analysis helped identify several active analogues of the hit compound, which resulted in a potential lead compound (LQZ-7F) that inhibits survival of multiple cancer cell lines with low micromolar IC50, suppresses xenograft tumor growth, and inhibits survivin in vivo. MD Simulation analysis of water trafficking. MD simulations of survivin dimers and water trafficking were carried out using the AMBER9 package as previously described (27) . Crystal structure of survivin dimer with PDB code 1F3H was acquired from RCSB protein databank (2) .
Materials and Methods

Materials
Zinc parameters were developed by Y.P. Pang using the cationic dummy atom (cada) approach (29) . Survivin dimer was solvated in a truncated octahedron box with edges no closer than 10Å to any atom in the solute with appropriate number of counter ions added to neutralize each system. Particle Mesh Ewald (PME) was used to calculate the long-range electrostatic interactions and the nonbonded cutoff was set to 8.0 Å. Each system was equilibrated by a four-step protocol prior to the 20-ns production MD simulation.
Total buried dimeric interface areas and buried surface areas decomposed to each residue were calculated by areaimol of the CCP4 package. Dimerization core residues that have more than 75% solvent accessible area buried in the dimeric interface were selected. Survivin has one dimerization core unit consisting of four residues: Leu 98 and Phe 101 from one chain and same residues from another chain. This dimerization core entity is further validated by its water exchange rate determined via 20-ns water explicit MD simulation as previously described (27, 28) .
A sphere of 6 Å in radius was drawn from the center in the mass of the core. Water molecules that fell into the sphere during the simulation were monitored and their residue IDs were recorded by In-Silico Virtual Screening. Structure-based in-silico screening was performed as previously described (30, 31) . Briefly, the 3-D coordinates of survivin were acquired from PDB code 1F3H. Only one of the two chains was kept and the protein chain was prepared for docking.
Molecular surface was calculated using DMS (Distributed Molecular Surface) program. Partial charges and protons were added to the protein by UCSF Chimera Dock Prep module (32) . In-silico dock screening of 200,000 compounds from SPECS's library (www.specs.net) was performed using UCSF DOCK 6.0 program (33) . The docking of each compound was first scored with the DOCK GRID scoring function (34) . The top-scoring 1000 compounds were analyzed again and re-scored using the AMBER scoring function of DOCK 6.0 package (35) . These compounds were clustered using MOE (Molecular Operating Environment) program and visually examined using the UCSF Chimera ViewDock function. Final 100 compounds were selected based on the combination of GRID and AMBER score, drug likeness (Lipinski's rule of five), and on consideration of maximizing compounds from different clusters.
Non-denaturing PAGE. 1-g purified survivin were incubated with 20 µM candidate compounds, DMSO vehicle control, or different concentrations of LQZ-7 before mixing with equal volume of 2 sample buffer (100 mM Tris, pH 8.0, 20% glycerol, 0.005% bromophenol blue, 2% Triton X-100, and 100 mM DTT) followed by incubation at room temperature for 30 min.
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After centrifugation at 11,000 × g for 10 minutes, the supernatants were separated by electrophoresis on 15% Tris/glycine polyacrylamide gel followed by transfer to PVDF membrane for western blot analysis as previously described (36) .
Survival assays (MTT and colony formation).
These assays were performed as previously described (37, 38) . Briefly, MTT assay was performed by seeding 2500 cells in 96-well plate and cultured 24 hours before addition of survivin inhibitors at different concentrations and continuous culture for 3 days. The cells were then subjected to MTT assay. For colony formation assay, 100 cells/well were seeded in 6-well plates and cultured for 24 hours before addition of survivin inhibitors or DMSO vehicle. The cells were continuously cultured in the presence of survivin inhibitors or DMSO for 10-14 days followed by staining with crystal violet and counting manually.
Fluorogenic assay. Fluorogenic assay was performed as previously described (39) . Briefly, LQZ-7 was pre-incubated without or with 10 µg purified survivin for 30 min at Apoptosis assay. Annexin V apoptosis assay was performed using a kit as described by the manufacturer (Invitrogen). Briefly, treated cells were harvested after washing with PBS and then resuspended in annexin-binding buffer (10mM HEPES, pH7.4, 120 mM NaCl, 2.5mM CaCl2) at the density of 1×10 6 cells/ml. After addition of Alexa Fluor 488 annexin V and propidium iodide, the cells were incubated for 15 minutes at room temperature followed by dilution with annexinbinding buffer and FACS analysis of fluorescence emission at 530 nm and 575 nm with 488 nm excitation.
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Half-life determination and effect of proteasome inhibitors on survivin degradation. The effect of survivin inhibitors on the half-life of survivin was determined as previously described (40) . Briefly, PC-3 or DU145 cells were pre-treated with 2 µM cycloheximide for 1 hour followed by incubation without or with 9 µM LQZ-7 or 5 µM LQZ-7F for different times. The cells were then harvested for Western blot analysis of survivin.
For the proteasome inhibitor rescue experiment, PC-3 cells were seeded in 10-cm dishes at 
Results
Analysis of dimerization domain of survivin.
To effectively target the dimerization domain of survivin, we first analyzed the dimerization interface to identify residues that are critical for survivin dimerization as targets for in-silico screening. The interacting residues between the two 9 identical subunits are comprised of residues 6-10, ). About 80% of these residues are hydrophobic, which is comparably high considering the average of non-polar interaction is only ~50% in dimeric proteins 1 . The dimeric survivin has a total calculated solvent accessible area of 18,039 Å 2 . The buried accessible area in the dimeric interface of a monomeric survivin is 550 Å 2 and it occupies only 6% of the total accessible area of a monomer (9,044 Å 2 ), which is much less than the average value (~20%) in dimeric or oligomeric proteins 1, 2, 3 . The relatively small area and the high hydrophobicity of the interactive surface indicate that it may be a good target site for drug discovery.
Previously, we found that dimeric proteins may have dimerization core units that are sealed from water penetration and are critical for homo-dimerization (27) . Further analysis of the dimeric interface using our previously described computational approach (27) shows that survivin has one dimerization core unit consisting of four residues, Leu 98 and Phe 101 from one subunit and the same residues from another subunit (Fig. 1A) . Water exchange rate in this dimerization core unit was determined by performing 20-ns water explicit MD simulation and a computational method developed by us previously (27) . As shown in Fig. 1B , few water molecules moved in or out of the dimerization core during the 20-ns simulation with an estimated water exchange rate of 0.5 water/200 ps, which is comparable with that of the 14-3-3σ dimerization core (27) . It is, however, significantly lower than that of the mutant 14-3-3σ molecule, which lost dimerization activity with a much higher water exchange rate (>4 water/200 ps). These findings suggest that the dimerization and PC-3 cells. Consequently, these compounds were chosen for further investigation.
The selected compounds were tested for their ability to dissociate survivin dimers using purified survivin and non-denaturing PAGE analysis. As shown in Fig. 2A , compound #7 (named LQZ-7 with structure shown in Fig. 2B ) was able to affect the mobility of purified survivin, presumably by dissociating the dimeric survivin into monomers. To confirm its activity and test its potential selectivity, we had LQZ-7 resynthesized and performed a dose-response analysis of its activity in dissociating dimeric survivin and an irrelevant control but similar dimeric protein, 14-3-3σ. Although 100 µM LQZ-7 appears to be required to completely dissociate dimeric survivin (Fig. 2C ), LQZ-7 at 100 µM had no effect on 14-3-3σ dimerization (Fig. 2D) . We also performed non-denaturing PAGE analysis of nascent proteins synthesized in a cell-free system in the presence of LQZ-7. As shown in Fig. 2E , 20 µM LQZ-7 achieved a complete inhibition of survivin dimerization. Together, these findings suggest that LQZ-7F can inhibit dimerization of nascent survivin and dissociate existing dimeric survivin with selectivity over other homo-dimeric proteins such as 14-3-3σ. The finding that less LQZ-7 is required to completely inhibit 11 dimerization of nascent survivin than to completely dissociate existing dimeric survivin suggests that inhibiting dimerization of newly synthesized proteins may be dynamically favorable than dissociating the existing dimeric proteins.
To verify that LQZ-7 indeed binds to survivin and inhibits survivin dimerization, we took advantage of the intrinsic fluorescent property of LQZ-7 and performed a fluorogenic titration assay in the presence or absence of survivin as previously described (39) . Fig. 2F shows that the intrinsic fluorescence of LQZ-7 dramatically increases in the presence of recombinant survivin, indicating that LQZ-7 likely interacts with survivin. The Kd of LQZ-7 binding to survivin is estimated to be ~0.24±0.11 µM.
LQZ-7 accelerates proteasome-dependent degradation of survivin. Exposure of hydrophobic interface of a dimeric protein often leads to conformational change (24, 25) , which causes destabilization and degradation of the protein by proteasome or autophagy (26) . We, thus,
hypothesized that LQZ-7 may cause proteasome-dependent degradation of survivin by dissociating survivin dimers and exposing the hydrophobic dimeric interface. To test this hypothesis, we first treated DU145 cells with LQZ-7 for different times followed by determination of endogenous survivin using Western blot analysis. Fig. 3A shows that LQZ-7 treatment indeed reduces survivin protein level compared with vehicle control treatment. Similar results were also observed with PC-3 cells (data not shown). However, LQZ-7 treatment had no effect on the level of survivin mRNA as determined using real time RT-PCR (Fig. 3B) . LQZ-7 treatment also effectively reduced the level of ectopic Flag-tagged survivin in HEK293 cells under the control of an exogenous CMV promoter (Fig. 3C ). These observations together suggest that survivin loss induced by LQZ-7 is likely at the protein but not mRNA level.
We next determined if LQZ-7 causes survivin degradation by examining its effect on survivin half-life. For this purpose, DU145 and PC-3 cells were pre-treated with cycloheximide to inhibit synthesis of new proteins followed by treatment with LQZ-7 for different times. Fig. 3D-E show that the half-life of survivin is 1.5-2.5 hrs in control-treated DU145 and PC-3 cells, consistent with previously reported survivin half-life (42, 43) . However, following LQZ-7 treatment the halflife of survivin was reduced to ~30 min. Co-treatment with a proteasome inhibitor, MG132 or bortezomib, reversed LQZ-7-induced survivin loss (Fig. 3F) , consistent with a previous report that survivin degradation is mediated by the proteasome (44) . We also found that LQZ-7 does not inhibit survivin protein synthesis as determined using [ Together, the above findings suggest that LQZ-7 may cause proteasome-dependent survivin degradation possibly by inhibiting dimerization and exposing the hydrophobic core residues of survivin.
Characterization of LQZ-7 analogues. Although LQZ-7 dissociates survivin dimer in vitro
and causes survivin degradation in cells, cell-based cytotoxicity assays showed that the IC50 of LQZ-7 in human PC-3 and DU145 cells was ~25 µM (Fig. 4B) . The modest IC50 may be due to the possibility that the carboxyl group in LQZ-7 ( LQZ-7A, D, and E had no effect on the level of Flag-tagged survivin, LQZ-7B, C, and F all reduced survivin protein level. It appears that LQZ-7C and F completely eliminated survivin whereas the parent compound LQZ-7 did not, consistent with their lower IC50 than the parent compound. The fact that LQZ-7E has high IC50 and does not reduce survivin protein suggests that LQZ-7E may not bind to and inhibit survivin. It remains unknown why LQZ-7A and D have no effect on survivin level while maintaining low IC50 (see Discussion).
Of the two analogous (LQZ-7C and F) that have the best IC50 and ability to eliminate survivin, LQZ-7F is unique, smaller, and simpler in structure with a primary amine group as an advantage for further study (see below). Thus, we elected to pursue LQZ-7F further as a potential lead and tested its activity in suppressing the expression and inducing degradation of endogenous survivin. Similar as LQZ-7, LQZ-7F effectively suppressed endogenous survivin expression in both DU145 and PC-3 cells (Fig. 4D ) and increased degradation of endogenous survivin (Fig. 4E) . Furthermore, proteasome inhibitors MG132 and bortezomib both were able to rescue LQZ-7F-induced survivin degradation (Fig. 4F) . Thus, LQZ-7F, similar as its parent compound LQZ-7, also induces survivin degradation in a proteasome-dependent manner.
LQZ-7F interaction with survivin. To investigate if LQZ-7F indeed binds to survivin, we took
advantage of the primary amine group and immobilized LQZ-7F onto CNBr-activated Sepharose for a pull-down assay using purified survivin. As shown in (Fig. 5A ). As shown in Fig. 5C , 54-69% apoptosis for PC-3 and 66-98% apoptosis for HL60 cells were generated following treatments with 5-10 µM LQZ-7F. These findings were further validated by determining the cleavage of PARP-1, a substrate of caspases during execution of apoptosis, in both PC-3 and HL60 cells following LQZ-7F treatments (Fig. 5D ).
Finally, we tested survivin expression in all 13 cell lines (Fig. 5E ) and performed a correlation analysis between survivin level and IC50. As shown in Fig. 5F , the IC50 values strongly associate with survivin protein level in these cells with a Pearson correlation coefficient of 0.52, indicating that LQZ-7F may suppress the survival of these cancer cells by acting on survivin.
LQZ-7F treatments disrupt microtubule structure and cause mitotic arrest. Survivin has been shown to have dual functions in inhibiting apoptosis and in promoting cell cycle progression
(1). The later was thought to derive from survivin action in destabilizing microtubules both in vitro and in vivo (45, 46) . Thus, to further determine LQZ-7F effect on survivin, we analyzed microtubule structure following LQZ-7F treatment in PC-3 cells. As shown in Fig. 6 , the control DMSO-treated cells have orderly microtubule fibers in all cells. However, the microtubule structure was severely disrupted following LQZ-7F treatments. It also appears that many cells are arrested in mitotic phase with aberrant spindles following LQZ-7F treatments. These observations are consistent with the role of survivin in microtubule dynamics (47, 48) and in proper chromosome segregation and cytokinesis (49, 50) .
LQZ-7F inhibits growth of xenograft tumors by inhibiting survivin. We next determined if
LQZ-7F is active in suppressing tumor growth in vivo using a xenograft animal model. For this purpose, NOD/SCID mice were first implanted subcutaneously with PC-3 cells to establish xenograft tumors. PC-3 was chosen because it has the highest IC50 (Fig. 5) . When the xenograft tumor reached the size of ~100 mm 3 , the mice were randomized into two groups and treated with 25 mg/kg LQZ-7F or vehicle control via IP injection once every three days for a total of 8 treatments. As shown in Fig. 7A , the growth of xenograft tumors was significantly inhibited in the LQZ-7F-treated group compared to the tumors in vehicle control-treated group. However, the body weight of mice in the treatment group remained constant after multiple dosing (Fig. 7B) , indicating that LQZ-7F may not cause major toxicity after multiple dosing. In fact, the body weight of the control group dropped slightly possibly due to disease burden of xenograft tumors. This symptom appears to be alleviated by LQZ-7F treatment, consistent with the smaller tumor size in the treatment group.
The final dissected tumors in the treatment group appear to be small and round with smooth surface whereas the tumors of the control group appear to be irregular and bigger (Fig. 7C) ,
suggesting that the tumors in the treatment group are confined whereas the tumors in the control group are aggressive. The average weight of the tumors in the treatment group is significantly less than that in the control group (Fig. 7D) . The LQZ-7F-treated tumors also appear to have more apoptotic cells as indicated by condensed chromatin than the control-treated tumors (Fig. 7E ).
Western blot and IHC staining analyses showed that survivin in xenograft tumors of the LQZ-7F-treated group was dramatically reduced compared with the tumors of the control-treated group (Fig. 7E-F) , suggesting that the effect of LQZ-7F on xenograft tumor growth may be due to its binding to survivin and induction of survivin degradation in vivo.
Discussion
In this study, using in-silico screening targeting the critical hydrophobic core residues in the dimeric interface following detailed analysis of the buried surface area, we successfully This study provides a proof-of-concept that the hydrophobic core residues in the dimeric interface of undruggable homo-dimeric proteins can be targeted for drug discovery. Combining computational analysis of the dimeric interface to first identify these core units with in-silico screening, as demonstrated here, is likely a viable approach that will help succeed in identifying small molecule compounds inhibiting dimerization of the target protein.
The finding that LQZ-7 and its analogues induce survivin degradation is consistent with the concept that exposure of the hydrophobic interface of a dimeric protein often lead to conformational change (24, 25) , which causes destabilization and degradation of the protein by the proteasome or autophagy (26) . Interestingly, not all LQZ-7 analogues induced survivin degradation. LQZ-7E had no effect on survivin expression, consistent with its lack of inhibitory effect on cell survival, suggesting that LQZ-7E may not bind to and induce survivin degradation. not form heterodimer with other proteins due to existence of the compound in the interface. It is also possible that mutation of the hydrophobic core residues reduced the hydrophobicity of the interface and, thus, the protein could escape from the cell quality control system while binding of the small molecule compound to the interface may increase the hydrophobicity and attract the quality control system. Future studies are warranted to test these possibilities.
It is also noteworthy that a small molecule compound, LLP3, was synthesized previously based on the Abbot8, a survivin inhibitor obtained via a NMR-based screening. LLP3 was thought to bind to the dimerization interface of survivin (39) . However, LLP3 had no effect on survivin dimerization or its expression. Instead, it inhibited interaction between survivin and its partner Ran Effect of LQZ-7F on survivin stability determined using cycloheximide (CHX) chasing as described in Fig. 3 . 
